肿瘤细胞治疗研究
英文原题：Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.
这些结果提示，axi-cel 可能为许多患有这些癌症的人提供长期疾病控制。
这篇摘要讲的是什么？这是一项名为 ZUMA-5 的临床研究的摘要。该研究考察了癌症治疗药物 axicabtagene ciloleucel（axi-cel）对惰性非霍奇金淋巴瘤（iNHL）患者的疗效，包括滤泡性淋巴瘤（FL）和边缘区淋巴瘤（MZL）。FL 和 MZL 是影响一种称为 B 细胞的白细胞的癌症。Axi-cel 是一种嵌合抗原受体（CAR）T 细胞疗法。Axi-cel 由患者自身的免疫细胞制成，帮助身体对抗癌症。该研究是如何进行的？ZUMA-5 研究纳入了 159 名 iNHL 患者（127 名 FL 和 31 名 MZL）。试验参与者是癌症在治疗后复发或癌症对首次治疗无反应的患者。所有患者此前均至少接受过 2 种癌症治疗。研究人员考察了 axi-cel 的疗效以及患者治疗后的副作用。该试验中的患者已被随访超过 5 年。结果如何？约 5 年后，90% 的患者对治疗有反应。75% 的患者癌症完全消失。在 5 年时，50% 的患者存活且癌症未恶化或复发。约 10 人中有 7 人在治疗后 5 年时仍然存活。在 5 年时，超过半数患者既存活，且在 axi-cel 治疗后的 5 年内不需要任何进一步的癌症治疗。Axi-cel 最常见的副作用发生在治疗后不久，与免疫反应过度活跃以及大脑和神经系统工作方式的变化有关。这些副作用通常是暂时的。在 5 年时，15% 的患者因与癌症无关的原因死亡，其中感染是最常见的原因。结果意味着什么？Axi-cel帮助约一半的FL或MZL患者在没有癌症恶化或需要更多治疗的情况下生活。这些结果表明，axi-cel可能为许多患有这些癌症的人提供长期疾病控制。副作用大多可控，且发生在治疗早期，长期内新出现的副作用极少。临床试验编号：NCT03105336。
What is this summary about? This is a summary of a clinical study called ZUMA-5. The study looked at how well the cancer treatment axicabtagene ciloleucel (axi-cel) worked for people with indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma (FL) and marginal zone lymphoma (MZL). FL and MZL are cancers that affect a type of white blood cell called a B cell. Axi-cel is a type of chimeric antigen receptor (CAR) T-cell therapy. Axi-cel is made from a person s own immune cells and helps the body fight cancer. How was the study conducted? The ZUMA-5 study included 159 people with iNHL (127 with FL and 31 with MZL). The trial participants were people whose cancer had come back after treatment or whose cancer had not responded to their first treatment. All people had received at least 2 previous treatments for their cancer. Researchers looked at how well axi-cel worked and what side effects people had after treatment. People in this trial have been followed for over 5 years. What were the results? After about 5 years, 90% of people had responded to treatment. For 75% of people, their cancer completely went away. At 5 years, 50% of people were alive without the cancer getting worse or coming back. Around 7 in 10 people were still alive 5 years after treatment. At 5 years, more than half of people were both alive and had not needed any further cancer treatment in the 5 years since their axi-cel treatment. The most common side effects of axi-cel happened soon after treatment and were related to an overactive immune response and changes in how the brain and nervous system work. These side effects were usually temporary. At 5 years, 15% of patients had died due to causes not related to their cancer, with infections being the most common cause. What do the results mean? Axi-cel helped about half of people with FL or MZL live without their cancer getting worse or needing more treatment. These results suggest that axi-cel may offer long-term disease control for many people with these cancers. The side effects were mostly manageable and occurred early after treatment, with very few new side effects in the long term. Clinical trial number : NCT03105336.
MEMBER ACCOUNT
登录成功会直接打开下一页。
